Information Provided By:
Fly News Breaks for May 13, 2015
OREX
May 13, 2015 | 08:08 EDT
Leerink lowered its price target for Orexigen to $8 to reflect an increased risk profile given the company's dispute with Takeda. The firm believes "considerable risk" is already priced in with the stock below $6, but it expects the overhang to remain until the company resolves its disagreement with Takeda and executes on other key goals. Leerink keeps an Outperform rating on Orexigen.
News For OREX From the Last 2 Days
There are no results for your query OREX